Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer

  • Tarun Mehra,
  • Judith E. Lupatsch,
  • Thibaud Koessler,
  • Konstantin Dedes,
  • Alexander Reinhard Siebenhüner,
  • Roger von Moos,
  • Andreas Wicki,
  • Matthias E. Schwenkglenks

The third author’s name is spelled incorrectly. The correct name is: Thibaud Koessler. The correct citation is: Mehra T, Lupatsch JE, Koessler T, Dedes K, Siebenhüner AR, von Moos R, et al. (2024) Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer. PLoS ONE 19(4): e0301271. https://doi.org/10.1371/journal.pone.0301271

Reference

  1. 1. Mehra T, Lupatsch JE, Kössler T, Dedes K, Siebenhüner AR, von Moos R, et al. (2024) Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer. PLOS ONE 19(4): e0301271. https://doi.org/10.1371/journal.pone.0301271 pmid:38573891

Citation: Mehra T, Lupatsch JE, Koessler T, Dedes K, Siebenhüner AR, von Moos R, et al. (2024) Correction: Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer. PLoS ONE 19(12): e0315976. https://doi.org/10.1371/journal.pone.0315976

Published: December 12, 2024

Copyright: © 2024 Mehra et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.